0000078003-18-000080.txt : 20181017
0000078003-18-000080.hdr.sgml : 20181017
20181017171716
ACCESSION NUMBER: 0000078003-18-000080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181015
FILED AS OF DATE: 20181017
DATE AS OF CHANGE: 20181017
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PFIZER INC
CENTRAL INDEX KEY: 0000078003
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 181126966
BUSINESS ADDRESS:
STREET 1: 235 E 42ND ST
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 2125732323
MAIL ADDRESS:
STREET 1: 235 E 42ND ST
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER NAME:
FORMER CONFORMED NAME: PFIZER CHARLES & CO INC
DATE OF NAME CHANGE: 19710908
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2018-10-15
0
0001737287
Allogene Therapeutics, Inc.
ALLO
0000078003
PFIZER INC
235 E 42ND ST
NEW YORK
NY
10017
0
0
1
0
Common Stock
2018-10-15
4
C
0
21976484
A
21976484
D
Common Stock
2018-10-15
4
P
0
55556
18
A
22032040
D
Series A-1 Convertible Preferred Stock
2018-10-15
4
C
0
4185997
0
D
Common Stock
21976484
0
D
In connection with the closing of the Issuer's initial public offering, each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") converted into the Issuer's common stock on a 1-for-5.25 basis without payment or consideration. The Preferred Stock had no expiration date.
/s/Susan Grant, Assistant Secretary on behalf of Pfizer Inc.
2018-10-17